Bedford,balenciaga scarpe uomo MA-based MicroCHIPS today announced that Novartis’s early-stage-company investment arm, Novartis Venture Fund (NVF), led a $13.4 million round of funding in the firm and its “smart” drug delivery and biosensing devices. CSK Venture Capital of Japan also participated in the round, joining existing MicroCHIPS investors Polaris Venture Partners, IDG Ventures, Medtronic, Boston Scientific, Intersouth Partners and Boston University Community Technology Fund. MicroCHIPS’s technology is designed to improve therapeutic control, reduce painful interventions and help maintain balenciaga scarpe uomo and improve health for diabetes and osteoporosis sufferers. Of his firm’s investment, NVF global head Reinhard Ambros said, “Novartis sees tremendous opportunity in the development of innovative devices that can be used to sense a patient’s condition and precisely deliver highly potent molecules to critically ill patients. MicroCHIPS’ drug delivery and biosensing devices have the potential to revolutionize monitoring and therapy for millions of patients suffering from metabolic and cardiovascular diseases.”http://www.sneaker2018.it/